Paul Tudor Jones Coherus Bio Sciences, Inc. Transaction History

Tudor Investment Corp Et Al

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.59 - $3.85 $27,934 - $67,640	-17,569 Reduced 31.64%	37,952 $126,000
Q3 2023 Nov 15, 2023	BUY	$3.74 - $5.45 $47,999 - $69,945	12,834 Added 30.07%	55,521 $207,000
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $2,588 - $5,668	683 Added 1.63%	42,687 $182,000
Q1 2023 May 15, 2023	BUY	$5.89 - $10.52 $30,486 - $54,451	5,176 Added 14.05%	42,004 $287,000
Q4 2022 Feb 14, 2023	BUY	$5.69 - $10.07 $75,210 - $133,105	13,218 Added 55.98%	36,828 $292,000
Q3 2022 Nov 14, 2022	SELL	$7.17 - $13.87 $1.09 Million - $2.1 Million	-151,480 Reduced 86.52%	23,610 $227,000
Q2 2022 Aug 15, 2022	SELL	$5.86 - $13.23 $79,760 - $180,073	-13,611 Reduced 7.21%	175,090 $1.27 Million
Q1 2022 May 16, 2022	SELL	$10.92 - $16.41 $82,129 - $123,419	-7,521 Reduced 3.83%	188,701 $2.44 Million
Q4 2021 Feb 14, 2022	BUY	$15.81 - $18.99 $3.1 Million - $3.73 Million	196,222 New	196,222 $3.13 Million
Q1 2020 May 15, 2020	SELL	$11.67 - $22.53 $192,449 - $371,542	-16,491 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $269,298 - $352,412	16,491 New	16,491 $297,000
Q2 2019 Aug 14, 2019	SELL	$13.1 - $22.1 $403,597 - $680,878	-30,809 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$8.38 - $15.5 $258,179 - $477,539	30,809 New	30,809 $420,000
Q4 2017 Feb 14, 2018	SELL	$8.35 - $14.4 $162,841 - $280,828	-19,502 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$11.1 - $14.5 $216,472 - $282,779	19,502	19,502 $260,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.